EUVIMEDEUVIMED entdecken
Open Access

Effects of DNA methylase inhibitors in a murine model of severe BPD

Kathryn M Heyob, Zahra Khuhro, Aiman Q Khan, Dorian Brown, Trent E Tipple, Lynette K Rogers

Respiratory Physiology & Neurobiology · 2023

DOI: 10.1016/j.resp.2023.104060 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Respiratory Physiology & Neurobiology, 2023. Verfasst von Kathryn M Heyob und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Perinatal Research, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA. Hauptthemen laut MEDLINE: Bronchopulmonary Dysplasia, Hyperoxia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, Nationwide Children's Hospital, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

DNA methylation is necessary for developmental gene regulation, but adverse environments result in aberrant methylation and gene silencing. The current pilot study tested the hypothesis that treatment with DNA methylation inhibitors (decitabine; RG108) would improve alveolarization in a newborn murine model of severe bronchopulmonary dysplasia. Newborn mice exposed to maternal inflammation (LPS) and neonatal hyperoxia (85% O2) were treated with decitabine (p3, 0.1 mg/kg; p2, 4, 6, 0.1 mg/kg; or p2, 4, 6, 0.15 mg/kg) or RG108 (p3, 0.0013 mg/kg) delivered intranasally. Modest improvements in alveolarization were observed with decitabine, but no differences were observed with RG108. Attenuated phospho-SMAD2/3 levels and greater surfactant protein C protein levels compared to vehicle were observed with some tested doses. No detrimental side effects were observed with the doses used in this study. In summary, our pilot investigations identified a safe dose for intranasal administration of both methylation inhibitors and provides a foundation for further studies into methylation inhibitors in the context of neonatal lung injury.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bronchopulmonary DysplasiaHyperoxiaAnimalsMiceAnimals, NewbornDecitabineDisease Models, AnimalDNALungPilot ProjectsPhthalimidesTryptophan

Stichwörter der Autor:innen

AlveolarizationDNMTRG108TGFβ1decitabine

Substanzen

DecitabineDNARG108PhthalimidesTryptophan

Autor:innen und Institutionen

  • Center for Perinatal Research, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.
  • Section of Neonatal-Perinatal Medicine, Department of Pediatrics, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
  • Center for Perinatal Research, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA; Department of Pediatrics, The Ohio State University, Columbus, OH, USA. Electronic address: Lyne…

Förderung

  • NICHD NIH HHS
  • Nationwide Children's Hospital
  • National Institutes of Health

Zitieren

APA

Heyob, K. M., Khuhro, Z., Khan, A. Q., Brown, D., Tipple, T. E., & Rogers, L. K. (2023). Effects of DNA methylase inhibitors in a murine model of severe BPD. Respiratory Physiology & Neurobiology. https://doi.org/10.1016/j.resp.2023.104060

Vancouver

Heyob KM, Khuhro Z, Khan AQ, Brown D, Tipple TE, Rogers LK. Effects of DNA methylase inhibitors in a murine model of severe BPD. Respiratory Physiology & Neurobiology. 2023. doi:10.1016/j.resp.2023.104060

BibTeX
@article{Heyob2023,
  author = {Heyob, Kathryn M and Khuhro, Zahra and Khan, Aiman Q and Brown, Dorian and Tipple, Trent E and Rogers, Lynette K},
  title = {Effects of DNA methylase inhibitors in a murine model of severe BPD},
  journal = {Respiratory Physiology & Neurobiology},
  year = {2023},
  doi = {10.1016/j.resp.2023.104060}
}
Kostenlos starten →